Evidence map›Paper›PMID 31682261›Full record

ArticleThe Journal of infectious diseases2020

Impact of Universal Antiretroviral Treatment Eligibility on Rapid Treatment Initiation Among Young Adolescents with Human Immunodeficiency Virus in Sub-Saharan Africa.

Olga Tymejczyk, Ellen Brazier, Kara Wools-Kaloustian, Mary-Ann Davies, Madeline Dilorenzo, Andrew Edmonds, Rachel Vreeman, Carolyn Bolton, Christella Twizere, Nicollate Okoko and 6 more

Abstract read
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Olga TymejczykInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.
Ellen BrazierInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.
Kara Wools-KaloustianIndiana University School of Medicine, Indianapolis, Indiana, USA.
Mary-Ann DaviesCentre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Madeline DilorenzoInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.
Andrew EdmondsDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Rachel VreemanDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Carolyn BoltonCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
Christella TwizereCentre Hospitalo-Universitaire de Kamenge, Bujumbura, Burundi.
Nicollate OkokoKenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Sam PhiriLighthouse Trust, Lilongwe, Malawi.
Gertrude NakigoziRakai Health Sciences Program, Kalisizo, Uganda.
Patricia LeloKalembelembe Pediatric Hospital, Kinshasa, Democratic Republic of the Congo.
Per von GrooteInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Annette H SohnTREAT Asia, amfAR-The Foundation for AIDS Research, Bangkok, Thailand.
Denis NashInstitute for Implementation Science in Population Health, City University of New York, New York, NY, USA.

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MALLORY O JOHNSON · 1988 to 2026
$93.6M
East Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Leslie Anne Enane, AGGREY SEMWENDERO SEMEERE · 2006 to 2026
$57.7M
Observational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
NIAID NIH HHS P30 AI027763NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299
6 · The paper itself

Abstract

backgroundYoung adolescents with perinatally acquired human immunodeficiency virus (HIV) are at risk for poor care outcomes. We examined whether universal antiretroviral treatment (ART) eligibility policies (Treat All) improved rapid ART initiation after care enrollment among 10-14-year-olds in 7 sub-Saharan African countries.

methodsRegression discontinuity analysis and data for 6912 patients aged 10-14-years were used to estimate changes in rapid ART initiation (within 30 days of care enrollment) after adoption of Treat All policies in 2 groups of countries: Uganda and Zambia (policy adopted in 2013) and Burundi, Democratic Republic of the Congo, Kenya, Malawi, and Rwanda (policy adopted in 2016).

resultsThere were immediate increases in rapid ART initiation among young adolescents after national adoption of Treat All. Increases were greater in countries adopting the policy in 2016 than in those adopting it in 2013: 23.4 percentage points (pp) (95% confidence interval, 13.9-32.8) versus 11.2pp (2.5-19.9). However, the rate of increase in rapid ART initiation among 10-14-year-olds rose appreciably in countries with earlier treatment expansions, from 1.5pp per year before Treat All to 7.7pp per year afterward.

conclusionsUniversal ART eligibility has increased rapid treatment initiation among young adolescents enrolling in HIV care. Further research should assess their retention in care and viral suppression under Treat All.

Indexed as

Health PolicyAdolescentAfrica South of the SaharaAnti-Retroviral AgentsChildEligibility DeterminationFemaleHIV InfectionsHumansLongitudinal StudiesMaleTime FactorsAnti-Retroviral AgentsadolescentsART eligibilityART initiationregression discontinuitysub-Saharan AfricaTreat All

Identifiers

PMID31682261
PMCPMC7530553

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.